Angiotensin-converting enzyme inhibitors (ACE-I) received 23 (27 %) SSc patients, angiotensin II receptor antagonists-5 (6 %), beta blockers-7 (8 %), diuretics-12 (14 %), calcium channel blockers-20 (23 %). The gene discussed is ACE; the disease is systemic sclerosis.